Latent Class Analysis Identifies Distinctive Behavioral Subtypes in Children with Fragile X Syndrome.

Walter E Kaufmann, Melissa Raspa, Carla M Bann, Julia M Gable, Holly K Harris, Dejan B Budimirovic, Reymundo Lozano, FORWARD Consortium
Author Information
  1. Walter E Kaufmann: Department of Human Genetics, Emory University School of Medicine, 615 Michael Street, Atlanta, GA, 30322, USA. walter.e.kaufmann@emory.edu. ORCID
  2. Melissa Raspa: RTI International, 3040 Cornwallis Road, Research Triangle Park, NC, 27709, USA.
  3. Carla M Bann: RTI International, 3040 Cornwallis Road, Research Triangle Park, NC, 27709, USA.
  4. Julia M Gable: RTI International, 3040 Cornwallis Road, Research Triangle Park, NC, 27709, USA.
  5. Holly K Harris: Texas Children's Hospital, 8080 North Stadium Drive, Houston, TX, 77054, USA.
  6. Dejan B Budimirovic: Kennedy Krieger Institute, 1741 Ashland Avenue, Baltimore, MD, 21205, USA.
  7. Reymundo Lozano: Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY, 10029, USA.

Abstract

Fragile X syndrome (FXS) is characterized by variable neurobehavioral abnormalities, which leads to difficulties in developing and evaluating treatments and in determining accurate prognosis. We employed a pediatric cross-sectional sample (1,072 males, 338 females) from FORWARD, a clinic-based natural history study, to identify behavioral subtypes by latent class analysis. Input included co-occurring behavioral conditions, sleep and sensory problems, autistic behavior scales (SCQ, SRS-2), and the Aberrant Behavior Checklist revised for FXS (ABC). A 5-class solution yielded the most clinically meaningful, pharmacotherapy independent behavioral groups with distinctive SCQ, SRS-2, and ABC profiles, and adequate non-overlap (≥ 71%): "Mild" (31%), "Moderate without Social Impairment" (32%), "Moderate with Social Impairment" (7%), "Moderate with Disruptive Behavior" (20%), and "Severe" (9%). Our findings support FXS subtyping, for improving clinical management and therapeutic development.

Keywords

References

  1. Pediatrics. 2017 Jun;139(Suppl 3):S183-S193 [PMID: 28814539]
  2. Am J Med Genet. 1999 Apr 2;83(4):286-95 [PMID: 10208163]
  3. Pediatrics. 2017 Jun;139(Suppl 3):S194-S206 [PMID: 28814540]
  4. Am J Med Genet C Semin Med Genet. 2010 Nov 15;154C(4):469-76 [PMID: 20981777]
  5. Am J Med Genet A. 2008 May 15;146A(10):1358-67 [PMID: 18412117]
  6. Pediatrics. 2014 Nov;134(5):995-1005 [PMID: 25287458]
  7. JAMA. 2008 Nov 26;300(20):2419-21 [PMID: 19033593]
  8. Brain Sci. 2020 Sep 30;10(10): [PMID: 33008014]
  9. Nat Rev Drug Discov. 2018 Apr;17(4):280-299 [PMID: 29217836]
  10. PLoS One. 2019 Dec 31;14(12):e0226811 [PMID: 31891607]
  11. Am J Intellect Dev Disabil. 2017 May;122(3):247-281 [PMID: 28452584]
  12. J Autism Dev Disord. 2017 Nov;47(11):3634-3645 [PMID: 28879490]
  13. J Autism Dev Disord. 2019 Nov;49(11):4595-4602 [PMID: 31468273]
  14. Child Neuropsychol. 2021 Oct;27(7):949-959 [PMID: 34002674]
  15. Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10767-10772 [PMID: 28923933]
  16. Genome Med. 2012 Dec 21;4(12):100 [PMID: 23259642]
  17. Autism Res. 2009 Apr;2(2):67-77 [PMID: 19455643]
  18. Pediatrics. 2009 Jan;123(1):378-90 [PMID: 19117905]
  19. Ment Retard Dev Disabil Res Rev. 2004;10(1):31-41 [PMID: 14994286]
  20. Autism Res. 2022 Mar;15(3):539-550 [PMID: 34967132]
  21. Am J Med Genet A. 2022 Mar;188(3):858-866 [PMID: 35148024]
  22. Front Pediatr. 2021 Dec 30;9:736255 [PMID: 35036394]
  23. Brain Sci. 2019 Jan 23;9(2): [PMID: 30678024]
  24. J Intellect Disabil Res. 2011 Nov;55(11):1064-77 [PMID: 21883598]
  25. J Autism Dev Disord. 2020 Sep;50(9):3276-3295 [PMID: 31342442]
  26. Am J Med Genet A. 2022 Apr;188(4):1029-1039 [PMID: 34889523]
  27. J Neurodev Disord. 2021 Apr 19;13(1):16 [PMID: 33874886]
  28. J Grad Med Educ. 2012 Sep;4(3):279-82 [PMID: 23997866]
  29. Dev Psychopathol. 2023 Aug;35(3):1188-1202 [PMID: 34866567]
  30. Am J Med Genet A. 2014 Jul;164A(7):1648-58 [PMID: 24700618]
  31. J Autism Dev Disord. 2012 Jul;42(7):1377-92 [PMID: 21972117]
  32. J Intellect Disabil Res. 2022 Mar;66(3):265-281 [PMID: 34984734]
  33. J Autism Dev Disord. 2020 Mar;50(3):1056-1063 [PMID: 31728808]

Grants

  1. U01DD001189/ACL HHS
  2. U01 DD000231/NCBDD CDC HHS
  3. U19 DD000753/NCBDD CDC HHS
  4. #U19DD000753/NCBDD CDC HHS
  5. K01 NS126736/NINDS NIH HHS
  6. contract 75D30120F09737/NCBDD CDC HHS
  7. # U01DD001189/NCBDD CDC HHS
  8. U01 DD001189/NCBDD CDC HHS
  9. U01DD000231/NCBDD CDC HHS

MeSH Term

Male
Female
Child
Humans
Fragile X Syndrome
Autism Spectrum Disorder
Latent Class Analysis
Cross-Sectional Studies
Social Behavior

Word Cloud

Created with Highcharts 10.0.0FragileXFXSbehavioral"ModeratesyndromeclassanalysisbehaviorSCQSRS-2ABCSocialImpairment"Latentcharacterizedvariableneurobehavioralabnormalitiesleadsdifficultiesdevelopingevaluatingtreatmentsdeterminingaccurateprognosisemployedpediatriccross-sectionalsample1072males338femalesFORWARDclinic-basednaturalhistorystudyidentifysubtypeslatentInputincludedco-occurringconditionssleepsensoryproblemsautisticscalesAberrantBehaviorChecklistrevised5-classsolutionyieldedclinicallymeaningfulpharmacotherapyindependentgroupsdistinctiveprofilesadequatenon-overlap≥ 71%:"Mild"31%without32%7%DisruptiveBehavior"20%"Severe"9%findingssupportsubtypingimprovingclinicalmanagementtherapeuticdevelopmentClassAnalysisIdentifiesDistinctiveBehavioralSubtypesChildrenSyndromeAutismsymptomatologyIntellectualdisabilityMaladaptivePhenotypes

Similar Articles

Cited By